Antigenic heterogeneity of human glioma tissue and cell lines (HGL) defined by monoclonal antibodies (MAs)

  • Carol J. Wikstrand
  • Friedrich C. Grahmann
  • Rodney D. McComb
  • Darell D. Bigner

Abstract

The antigenic heterogeneity of human glioma tissue (19 glioblastoma, 6 astrocytomas) and 13 human glioma-derived cell lines (HGL) was investigated with a panel of 20 monoclonal antibodies (MAs) which defined markers of glioma-associated (GL) or lymphoid distribution (LM). Results obtained from radioimmuno-assay, immunofluorescence, immunohistochemistry, absorption, and polyacrylamide gel analysis estab-lished the following: 1) In general, expression of multiple antigens within one system (GL) correlated with multiple antigen expression in the other (LM). 2) Within the LM panel, Thy-1 and HLA-A,B antigens were expressed by all HGL, whereas only 4/13 HGL were Ia positive, and 3/13 CALLA positive. T-cell marker expression was infrequent and sporadic. 3) Glioblastoma and astrocytoma tissues exhibited less hetero-geneity than HGL; high proportions expressed >75% of the GL specificities tested for. 4) Two MAs highly reactive with glioblastomas (>70% positive) were minimally reactive with astrocytomas (1/6). Glio-blastomas and HGL are antigenically complex and heterogeneous, but the identification of finite antigen distributions by large numbers of MAs may serve a prognostic significance.

Keywords

heterogeneity gliomas monoclonal antibodies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wikstrand CJ, Bigner SH, Bigner DD: Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res 43: 3327–3334, 1983PubMedGoogle Scholar
  2. 2.
    Carrel S, de Tribolet N, Gross N: Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells. Eur J Immunol 12: 354–357, 1982PubMedCrossRefGoogle Scholar
  3. 3.
    Seeger RC, Danon YL, Rayner SA, Hoover F: Definition of a THY-1 determinant of human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol 128: 983–989, 1982PubMedGoogle Scholar
  4. 4.
    Bigner DD, Bigner SH, Pontén J, Westcrmark B, Mahaley MS, Ruoslanti E, Herschman H, Eng LF, Wikstrand CJ: Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropath Exp Neurol 40: 201–229, 1981PubMedCrossRefGoogle Scholar
  5. 5.
    Wikstrand CJ, Bigner DD: Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies. Cancer Res 42: 267–275, 1982PubMedGoogle Scholar
  6. 6.
    Wikstrand CJ, Grahmann FC, McComb RD, Bigner DD: Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies. J Neuropath Exp Neurol 44: 229–241, 1985PubMedCrossRefGoogle Scholar
  7. 7.
    Festenstein H, Schmidt W: Variation in MHC antigenic profiles of tumour cells and its biological effects. Immunol Rev 60: 85–127, 1981PubMedCrossRefGoogle Scholar
  8. 8.
    Riethmüller G, Johnson J, Wank R et al.: HLA-DR expression on nonlymphoid human tumor cells: biochemical and histochemical studies with monoclonal antibodies. In: GL Wright (ed) Monoclonal Antibodies and Cancer. Academic Press, Inc, New York, 1983, pp 243–249Google Scholar

Copyright information

© Martinas Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • Carol J. Wikstrand
    • 1
    • 2
    • 3
  • Friedrich C. Grahmann
    • 1
    • 2
    • 3
  • Rodney D. McComb
    • 1
    • 2
    • 3
  • Darell D. Bigner
    • 1
    • 2
    • 3
  1. 1.Dept of PathologyDuke University Medical CenterDurhamUSA
  2. 2.Department of NeuropathologyUniversity HospitalZurichSwitzerland
  3. 3.Department of Pathology and Laboratory MedicineUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations